Gary Giarratano joins Radient Pharmaceuticals

Takes position of director of North American sales and marketing

Radient Pharmaceuticals Corporation (RPC) has appointed Gary Giarratano as director of North American sales and marketing. He will also be responsible for managing sales of the firm’s Onko-Sure in vitro diagnostic (IVD) cancer test.

Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.

‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.

You may also like

Manufacturing
Why CAPA keeps failing and what strong organisations do differently

Why CAPA keeps failing and what strong organisations do differently

This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Manufacturing
Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Cloud-based environmental monitoring helps life science organisations establish professional-quality monitoring from day one and scale as requirements evolve
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
Manufacturing
Streamlining supply chains from clinical trial to commercial scale

Streamlining supply chains from clinical trial to commercial scale

Vetter’s Ayse Hizli discusses commercial supply chain planning, digital visibility, resilience and cold-chain management from clinical development to market launch
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Research grade to GMP: how peptide quality requirements change as development progresses

Research grade to GMP: how peptide quality requirements change as development progresses

This article presents a practical guide to matching peptide characterisation, impurity control, traceability and manufacturing oversight with rising regulatory expectations across preclinical and clinical development
Manufacturing
Systech launches automated serialisation stations for pharmaceutical packaging

Systech launches automated serialisation stations for pharmaceutical packaging

Integrated systems combine printing, verification and tamper-evident sealing to improve packaging line efficiency
Subscribe now